Please use this identifier to cite or link to this item:
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/9589
Title: | Identification of potential serum biomarkers associated with HbA1c levels in Indian type 2 diabetic subjects using NMR-based metabolomics |
Authors: | YOUSF, SALEEM Batra, Hitender S. Jha, Rakesh M. Sardesai, Devika M. Ananthamohan, Kalyani CHUGH, JEETENDER Sharma, Shilpy Chhabra, Mohit SHANTHAMURTHY, CHETHAN D. KUMAR, NANJUDASWAMY VIJENDRA MARDHEKAR, SANDHYA VISHWESHWARA, SHARATH S. KIKKERI, RAGHAVENDRA et al. |
Keywords: | Biomarker Nuclear magnetic resonance Metabolomics O-phosphocholine Prediabetes 2024 |
Issue Date: | Apr-2024 |
Publisher: | Elsevier B.V. |
Citation: | Clinica Chimica Acta, 557, 117857. |
Abstract: | Background: The prevalence of type 2 diabetes mellitus (T2DM), a progressive metabolic disorder characterized by chronic hyperglycemia and the development of insulin resistance, has increased globally, with worrying statistics coming from children, adolescents, and young adults from developing countries like India. Here, we investigated unique circulating metabolic signatures associated with prediabetes and T2DM in an Indian cohort using NMR-based metabolomics. Materials and methods: The study subjects included healthy volunteers (N = 101), prediabetic subjects (N = 75), and T2DM patients (N = 108). Serum metabolic profiling was performed using 1 H NMR spectroscopy and major perturbed metabolites were identified by multivariate analysis and receiver operating characteristic (ROC) modules. Results: Of the 36 aqueous abundant metabolites, 24 showed a statistically significant difference between healthy volunteers, prediabetics, and established T2DM subjects. On performing multivariate ROC curve analysis with 5 commonly dysregulated metabolites (namely, glucose, pyroglutamate, o-phosphocholine, serine, and methionine) in prediabetes and T2DM, AUC values obtained were 0.96 (95 % confidence interval (CI) = 0.93, 0.98) for T2DM; and 0.88 (95 % CI = 0.81, 0.93) for prediabetic subjects, respectively. Conclusion: We propose that the identified metabolite panel can be used in the future as a biomarker for clinical diagnosis, patient surveillance, and for predicting individuals at risk for developing diabetes. |
URI: | https://doi.org/10.1016/j.cca.2024.117857 http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/9589 |
ISSN: | 0009-8981 1873-3492 |
Appears in Collections: | JOURNAL ARTICLES |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.